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Abstract
Technological advances and increased utilization of medical
testing and procedures have prompted greater attention to
ensuring the patient safety of radiation use in the practice of
adult cardiovascular medicine. In response, representatives
from cardiovascular imaging societies, private payers, gov-
ernment and nongovernmental agencies, industry, medical
physicists, and patient representatives met to develop goals
and strategies toward this end; this report provides an
overview of the discussions. This expert “think tank”
reached consensus on several broad directions including: the
need for broad collaboration across a large number of diverse
stakeholders; clarification of the relationship between med-
ical radiation and stochastic events; required education of
ordering and providing physicians, and creation of a culture
of safety; development of infrastructure to support robust
dose assessment and longitudinal tracking; continued close
attention to patient selection by balancing the benefit of
cardiovascular testing and procedures against carefully min-
imized radiation exposures; collation, dissemination, and
implementation of best practices; and robust education, not
only across the healthcare community, but also to patients,
the public, and media. Finally, because patient radiation
safety in cardiovascular imaging is complex, any proposed
actions need to be carefully vetted (and monitored) for
possible unintended consequences.
Introduction
Medical diagnosis and treatment has employed ionizing
radiation as an indispensable tool since its introduction by
Roentgen in 1895. Advances in medical imaging and
procedural technology and utilization growth have resulted
in an increase in radiation exposure in cardiovascular pa-
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low doses of ionizing radiation used in cardiovascular care
may lead to an increased lifetime risk of cancer, and whether
such risks can be justified in light of the established medical
benefits (1–9). Recently, the discussion has expanded be-
yond the medical and physics communities to capture the
attention of the media, patients, and lawmakers. In Febru-
ary 2010, the House Committee on Energy and Com-
merce’s Subcommittee on Health held a Hearing on Med-
ical Radiation: An Overview of the Issues (10), which was
followed in March 2010 by a public meeting of the Food
and Drug Administration, Device Improvements to Reduce
Unnecessary Radiation Exposure from Medical Imaging
(11,12). Both of these meetings discussed the need to
regulate radiation exposure in the clinical setting. Despite
these intense efforts by multiple stakeholders, many unan-
swered questions remain.
Radiation is an unavoidable part of our daily lives, with
varying levels of background exposure from natural sources
including radionuclides in our bodies, cosmic rays, ground
sources, and radon (13). Although unnecessary radiation ex-
posure is clearly undesirable, the judicious and appropriate use
of low levels of ionizing radiation in medical applications is
intrinsic to the current state of the art of cardiovascular care. Its
application contributes to many other advances that have
remarkably reduced morbidity and mortality from the Amer-
ica’s number 1 killer (14). Thus, the effective diagnosis and
treatment of cardiovascular disease (CVD) often requires some
exposure to radiation (15–17), and the goal should be appro-
priate use rather than the elimination of radiation exposure
(18). The balance between the benefits and risks associated
with ionizing radiation must be evaluated in every clinical
scenario in order to provide optimal care. For justified proce-
dures, exposure should be optimized to give the lowest possible
dose while maintaining image quality to give the highest
possible accuracy. For example, in older patients and those
with life-threatening CVDs, the benefits of accurate diagnosis
and optimal management that are facilitated by imaging are
likely to outweigh the minimal or theoretical risks of optimal
radiation exposure.
Defining and accomplishing optimal patient radiation
safety in adult cardiovascular medicine represents a complex
and difficult task. To develop practical approaches to these
strategies, in February 2011, the Duke Clinical Research
Institute (DCRI), the American College of Cardiology
Foundation (ACCF), and the American Heart Association
(AHA) convened a meeting of representatives of cardiovas-
cular imaging societies, government agencies, industry,
medical physicists, safety experts, and patient representa-
tives. The discussions at the Think Tank, therefore, repre-
sent the opinions and recommendations of the participants,
and not necessarily the policy of the ACCF or the organi-
zations providing representatives.
This report provides a review of the discussions and
strategic recommendations from the Think Tank to en-
hance patient radiation safety for cardiovascular imagingand procedures. Together, these deliberations provide a
robust and feasible road map for optimizing radiation safety,
reducing patient dose, and obtaining diagnostic quality
images while maintaining optimal cardiovascular care
through appropriate and best practice use of imaging for
diagnosis and to guide therapeutic procedures.
Contemporary Cardiovascular Therapy
and Increasing Radiation Exposure
CVD is responsible for 33.6% or 1 of every 3 deaths in the
United States, more than any other cause of death. An
estimated 82,600,000 American adults (1 in 3) have some
form of CVD, and the lifetime risk for any CVD is 2 in 3
for men and 1 in 2 for women (14). Given the high
prevalence and mortality associated with CVD, timely
diagnosis and treatment are crucial.
The development and clinical application of imaging mo-
dalities, such as radionuclide myocardial perfusion imaging,
echocardiography, computed tomography (CT), magnetic res-
onance imaging, fluoroscopy, and angiography have signifi-
cantly enhanced the diagnostic and therapeutic approach to
CVD by improving diagnosis and procedural guidance and
enabling less invasive treatments. These advances in early
diagnosis and management, coupled with improved treatment
of CVD, have contributed to a remarkable reduction in
morbidity and mortality; from 1997 to 2007 the death rate
from CVD declined 27.8% (14). Substantial growth in cardiac
imaging occurred concurrently with, and may have influenced,
the declining cardiovascular morbidity and mortality (19,20).
owever, the increased demand generated in response to the
ngoing technological evolution has resulted in a significant
ncrease in the general population’s exposure to ionizing
adiation for medical purposes. A recent report from the
ational Council on Radiation Protection and Measurements
stimated that the collective dose received from medical uses of
adiation in the United States increased by 600% between
980 and 2006 (13).
Overview of Patient Radiation Protection
in Cardiovascular Care
The biological effects of ionizing radiation fall into 2 broad
categories. Deterministic effects predictably occur above cer-
tain thresholds of absorbed dose to a specific tissue and
include skin erythema, epilation, and possibly even direct
cardiac toxicity. Stochastic effects are those in which radiation
causes damage that may result in a malignancy, usually at a
much later time. The risk and frequency of malignancies
caused by the levels of radiation used in medical imaging
remains undetermined and controversial. However, given
this uncertainty, it is critical to educate providers to mini-
mize dose by performing only diagnostic exams and proce-
dures that are appropriate and necessary, considering the
benefits and risks of alternative examinations or procedures
without radiation, and by using the best possible combina-
1835JACC Vol. 59, No. 20, 2012 Douglas et al.
May 15, 2012:1833–47 Cardiovascular Radiation Safety Conference Reporttion of equipment, dose, and protocols that will still result in
accurate and diagnostic studies. Such practices are aligned
with fundamental principles of radiation protection in
medicine (21,22,22a); a procedure is justified if it is the most
appropriate means of accomplishing the clinical goal and is
optimized by using the smallest necessary amount of radia-
tion that provides diagnostic image quality (ALARA, or
using a radiation dose As Low As Reasonable Achievable)
(23,24).
Dosimetry: Measuring Radiation Exposure
Essential to any discussion of radiation safety is the differ-
entiation between exposure and dose. Exposure is the
amount of radiation produced by the device and the subse-
quent ionization of air molecules and is typically and simply
measured in air. In comparison, the amount of energy
absorbed per unit tissue, referred to as the absorbed dose, is
much more relevant to the discussion of radiation risks.
Patient absorbed doses vary by organ and body region
within a patient. The absorbed dose cannot be measured
directly but can only be estimated for a given exam since
numerous patient- and exam-specific factors dramatically
alter how much radiation is absorbed in different patients for
the same imaging protocol from a given device. Thus, even
if the scanner-delivered exposure is constant, the number of
x-ray photons that reach various tissues and organs varies
greatly between individuals. Additional contributors to vari-
ability in radiation absorption include machine design and
capability, scanning techniques, and other technical param-
eters. Nevertheless, exposure can be a useful parameter for
benchmarking between imaging protocols and institutions.
In addition to the difficulty in measuring the unique dose
distribution for each patient for each test, radiation dosim-
etry metrics differ by imaging modality, making compari-
sons of exposures from different tests and assessing cumu-
lative dose for a given individual challenging. For
radionuclide studies, the administered activity, expressed in
standard international (SI) units of Becquerel (Bq), is the
standard measurable dosimetry parameter, and internal
absorbed doses to the patient may be calculated by standard
methods in milligrays per unit administered activity (25–27). One
millicurie, the traditional unit for activity, corresponds to 37
MBq. For fluoroscopy and cineangiography, the measurable
dosimetry parameters include total air kerma at the inter-
ventional reference point, measured in Grays (Gy), and the
air kerma-area product (28) measured in Gy  cm2. For
CT, the volume computed tomographic dose index (CT-
DIvol), expressed in SI units of milligrays (mGy) or dose-
length product (DLP) expressed in SI units of mGy/cm are
most commonly used (29).
The effective dose (E, reported in SI units of milliSiev-
erts, mSv) is sometimes used to facilitate comparisons of
radiation exposure across modalities and exams. Effective
dose is a surrogate for risk used in radiation protection that
reflects a whole-body estimate of the dose value that would
yield the stochastic risk equivalent to that of a givennonuniform partial-body exposure to ionizing radiation
such as occurs in medical imaging (25). Effective dose is a
generic estimate of risk with a wide margin of error and
cannot be measured directly, but instead is obtained from
modeling, simulation, and interpolation. Although effective
dose can be used to compare different scan protocols or
examinations performed with different imaging modalities
that use ionizing radiation, it cannot express the biological
risk specific to individual patients. However, note that
effective dose may be useful in comparisons of the stochastic
risk of different medical procedures in population groups
that receive ionizing radiation, against each other or against
background radiation, whereas direct organ dose calcula-
tions are better suited to optimize radiological procedures
that involve multiple organs. Despite these efforts at stan-
dardization, measurement of radiation exposure and risk is
controversial, and there is not universal agreement on the
appropriate approach.
Modeling the Potential Cancer Risk
Associated With Medical Radiation
The risk of malignancy attributable to “low dose” (100 mSv)
levels of ionizing radiation is extrapolated from follow-up of
survivors of the atomic bomb explosions in Hiroshima and
Nagasaki, Japan, in 1945 (30). The appropriateness of this
extrapolation is controversial because, in contrast to patients
who undergo repeated low-dose medical imaging over decades,
these subjects experienced a single episode of whole-body
exposure to different types and qualities of radiation (including
alpha particles) with higher doses delivered over seconds to
days. Nevertheless, the “linear no-threshold” (LNT) model
derived from these data is currently used as the standard model
of potential radiation risk in radiation protection, including the
Biological Effects of Ionizing Radiation (BEIR) VII report
(31). However, there are some concerns with use of LNT as a
standard. The concept of effective dose and the LNT hypoth-
esis were developed for occupational radiation protection and
not as predictive biological models for patients exposed to
radiation during medical imaging. Further, the assumption
inherent in LNT, that cancer risk increases linearly with dose
and that there is no dose level below which there is no risk, is
challenged by other models that are well covered elsewhere (32).
Finally, stochastic risks are random by definition, and therefore
should not be linearly related to cumulative exposures.
Based on the LNT model, the average lifetime risk of cancer
mortality in the general population attributable to an effective
dose of 1,000 mSv (an exposure equal to 50 to 500 typical
coronary CT angiograms or radionuclide perfusion studies) is
estimated at 5% to 7.9% (31). However, prospective, long-term
observational studies (33,34) have not unequivocally confirmed
an increased risk of solid cancers related to medical or occu-
pational low-dose radiation (100 mSv) delivered over many
years, thereby neither confirming nor refuting the LNT model.
This may be because the cancer risk is so small at this dose level
that accurate detection of excess risk of over those conveyed by
biological factors and other known carcinogens would require
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ological studies of radiation as a carcinogen are further com-
plicated by the long latency period of most radiation-induced
cancers. Despite this uncertainty, stochastic radiation risks
likely decrease with increasing age and are lower in men than
in women; findings that are particularly germane to the
population of patients with coronary artery disease.
Approaches to Radiation Safety
Approaches to patient radiation safety must be lifelong and
not confined to simply reducing the exposure during a single
test or procedure. From a patient standpoint, the American
College of Radiology and the National Council on Radia-
tion Protection and Measurements suggest that efforts can
be divided into those that occur before the imaging or
procedure, during the test or procedure to ensure that
exposure is minimized, and then afterwards to ensure
lifelong safety (35,36). The Joint Commission uses an
analogous construct in dividing the requirements for its
2011 Sentinel Event Alert into right test, effective processes,
safe technology, and safety culture (25,37–41).
Before imaging or procedures: Tests and procedures
utilizing radiation should be performed in the right patient,
for the right reason, at the right time, and alternatives to
radiation should be considered. Thus, the issue of radiation
protection is relevant for every clinician making imaging
and procedural decisions. The ACCF appropriate use cri-
teria (16,42–47) offer an important framework to ensure
appropriate use, whereas concomitant consideration of rel-
ative radiation dose levels may be helpful in balancing
efficacy and potential radiation exposure to the patient to
determine whether the procedure is justified (35). This step
is highly important since the increase in population expo-
sure has occurred in the setting of decreased radiation from
each individual test and therefore has resulted entirely from
increased use. The International Commission on Radiolog-
ical Protection (22,48) and AHA (25) have developed
reference levels for use as benchmarking and quality assur-
ance tools that may be helpful in estimating anticipated
exposure from proposed procedures.
Creation of a safe environment and education of ordering
and rendering providers must also occur before imaging is
performed. The increased attention to the importance of
radiation protection has led to both professional society and
accreditation body recommendations in these areas (41).
During imaging: Each rendering physician, laboratory,
and hospital must be responsible for optimizing the dose
delivered for each test or procedure. The need for greater
standardization is demonstrated by significant variations (up
to 13-fold) in radiation doses for similar types of imaging
procedures, within and across institutions for both coronary
CT angiography and nuclear imaging (3,4,49). Professional
societies have addressed these challenges through the cre-
ation of robust procedural and safety guidelines, includingthose from the American Society of Nuclear Cardiology, the
Society for Cardiovascular Angiography and Interventions,
the Society for Cardiovascular Computed Tomography, and
the Society of Nuclear Medicine (25,37–40,50). Newer
technology has already enabled dramatic dose reductions for
cardiac computed tomography angiography (e.g., prospec-
tive electrocardiogram-triggered axial imaging) and nuclear
(e.g., use of technetium instead of thallium, reduced-dose
imaging using high-sensitivity cameras) and holds promise
for additional future dose reduction. Additional attention to
dose management and optimization would be facilitated by
equipment capable of automatically providing radiation
exposure estimates for benchmarking, quality improvement,
and research, and by ensuring that users understand how to
properly operate the equipment.
After imaging: Although it is likely that more appropri-
ate utilization and further improvements in technology will
reduce overall radiation exposure to patients, these necessary
interventions are not sufficient to ensure patient safety across
multiple episodes of care for multiple diseases delivered by
many providers. Although cumbersome and burdensome to
providers of imaging services, reporting doses from individ-
ual exams using the electronic medical record or alternative
methods is essential as a quality improvement tool for the
purposes of benchmarking and radiation minimization.
However, tracking cumulative dose in a given individual is
both difficult to do accurately and has no clear value for
improving long-term patient safety, given the inherently
random nature of stochastic events. Further, whether or not
such information can be used to better inform decision
making on types of diagnostic studies to be performed for
each episode of care is unproven. One exception to this is
tracking exposure during a single episode of care involving
repeated or high exposure, such as percutaneous coronary
interventions or ablative treatment of arrhythmias, which
may put a patient at risk for deterministic effects. Similarly,
it is recommended that short-term follow-up be performed
after high-dose fluoroscopic procedures (i.e., 5 Gy) to
detect and treat any resulting deterministic effects.
Developing an Action Plan for
Cardiovascular Radiation Safety Stakeholders
The uncertainties surrounding the actual levels of patient
dose related to cardiovascular care, the assessment of poten-
tial competing benefits and risks, and the need to develop
practical approaches to radiation safety and education of
physicians, patients, and the public require the input and
expertise of many relevant stakeholders. Such collaboration
and cooperation recognizes the unique knowledge, perspec-
tives, and experiences of each group. Therefore, 1 of the
critical strategies in achieving the Think Tank goals was to
identify and bring together these stakeholders to join in
radiation safety improvement:
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ologists and physicists working in both the basic and
applied sciences perform much needed research about
the biological effects of radiation exposure and how to
quantify radiation dose.
• Healthcare professionals; professional and scientific
organizations: Physicians and physician societies are
primary stakeholders as requestors and providers of
testing that has been demonstrated to improve mor-
bidity and mortality and as the guarantors of optimum
safety for their patients. These groups are responsible
for developing and implementing optimal imaging
procedures and educational initiatives and should play
a collaborative role in developing standards and regu-
lations regarding radiation safety. In addition, they are
responsible for defining the content of undergraduate,
graduate, and continuing medical education. Nonphy-
sician staff are also critical to development and imple-
mentation of standards.
• Medical physicists: Although the role of physicists in
many cardiovascular facilities has been limited to
quality control testing of equipment and ensuring
compliance with state and federal regulations, their
knowledge base is invaluable in quality improvement
and education.
• Regulators: Federal agencies, including the Food and
Drug Administration and Nuclear Regulatory Com-
mission, and the state radiological health agencies are
responsible for creating testing standards and moni-
toring and ensuring compliance through regulation,
and for responding to proposed changes in protocols/
dosing that would minimize radiation exposure. Other
regulators, including accreditation agencies such as the
Joint Commission, the American College of Radiol-
ogy, and the Intersocietal Accreditation Commission,
promote safety and standardization through accredita-
tion of imaging and procedural laboratories.
• Payers: At a national level, the Centers for Medicare
and Medicaid Services (CMS) sets guidelines for any
facilities (hospital and independent imaging facilities)
seeking CMS reimbursement for imaging procedures.
Government and private payers are also in a unique
position to identify and possibly flag duplicate imaging
tests and procedures, especially when care may be provided
by multiple caregivers. In addition, payers are able to
provide incentives to providers to improve care and
radiation safety on multiple levels and need to be open
to rapidly “covering” and reimbursing/paying for mod-
ified procedures that would minimize radiation expo-
sure. On a patient level, payers should not use radiation
history alone as an independent factor in determining
authorization for a procedure.
• Industry: Industry can uniquely advance the develop-
ment of new technologies and make these features
available to providers and patients. Such features
include the ability to ensure diagnostic accuracy whiledelivering lower doses of radiation, tracking exposure,
and transferring dose values to structured reports and
the electronic health record. Both individually and
through organizations such as the Medical Imaging
and Technology Alliance, industry is able to assist with
standardization of dose measurement across tests,
protocols, and healthcare providers and with dissemi-
nation through education regarding exposure and pro-
motion of facility quality assurance practices.
• Patients, public, and media: In the absence of a
universal medical record, the patient may be the only
source of information regarding prior procedures and
radiation exposures. Further, as with all care, patients
should be educated to make informed decisions,
which implies a basic level of knowledge as well as
provider disclosure of potential radiation-associated
risks related to testing and procedures. In the
absence of a universal medical record, the patient
can take an active role by keeping a record of his/her
exams and question the need for tests so they are not
repeated unnecessarily.
Critical Areas and Strategies for Action
The Think Tank organizers identified 4 critical areas for
which experts were charged with defining 3 to 5 goals and
associated strategies required to achieve these including
methods, responsibilities, stakeholders, and implementation
time frame. The time frame was meant to convey the
urgency of the issue as well as relative priorities of different
recommendations. The topics were
1. Quantifying the estimated stochastic risks of low-dose
radiation associated with cardiovascular imaging and
therapeutic procedures.
2. Measuring and reporting radiation dose in cardiovascular
imaging and procedures.
3. Minimizing radiation dose for single episodes of care and
across entire systems of care.
4. Educating and communicating with multiple groups to
increase awareness and achieve goals in minimizing
exposure.
Group 1: Quantifying the Estimated Stochastic
Risks of Low-Dose Radiation Associated With
Contemporary Cardiovascular Imaging and
Therapeutic Procedures
Current, ongoing radiation biology and epidemiology
research efforts are robust but still insufficient to fully
address critical questions raised by the need for improved
radiation safety (51). Identified needs are presented in
Table 1 and as follows.
Basic and translational research into the mechanisms by
which radiation-induced cellular DNA damage and cellular
repair and misrepair mechanisms affect radiation-related
carcinogenesis (52,53) should be encouraged and supported,
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ship at the molecular and cellular level. Several areas of
research were identified as important:
1. Biological markers of injury. Currently, it is unknown
which, if any, clinically obtainable biological markers of
radiation injury (such as DNA double-strand breaks or
sister chromatid exchanges in blood samples) predict
radiation-induced cancer. Identification and clinically
available testing for such markers may allow better
patient risk stratification.
2. Models of injury. Mechanistic biology-based dose-
response models at the level of cellular protein abnor-
malities hold the promise of predicting malignancy
induction with better resolution than epidemiological
studies. Such new models are being used to study
recently identified potential confounders of the cur-
rent understanding of the dose-response relationship
at low-dose ionizing radiation, such as genomic insta-
bility (54), bystander effects (55), or adaptive re-
sponses (56). A National Institutes of Health work-
shop to further explore the opportunities in this area
would be an important first step toward dedicating
funding.
3. Because the science and methods of radiation dosimetry
are complex, better techniques for modeling and simu-
lation are needed to estimate radiation dose and the
potential biological impact. These same methods would
likely have relevance to the public secondary to applica-
tion related to occupational exposures, nuclear accidents,
or acts of war/terrorism.
Implementation: 2014 and ongoing.
Epidemiologic research is required to define the true
long-term risks of exposure, especially in those at high
risk (such as children or those with multiple, serial
exposures). The stochastic risks of serial low-dose expo-
sures are inadequately defined; research into statistical
Table 1. Strategies for Quantifying the Estimated Stochastic R
Contemporary Cardiovascular Imaging and Therapeutic Procedu
Strategy
Prim
Respon
asic and translational research in radiation biology ● Research
● Physicists
● Funding a
● Evaluate biological markers of cellular radiation injury as
predictors of radiation-induced cancer
● Determine the dose-response relationship between
radiation and molecular and cellular effects
● Better techniques for modeling and simulation to estimate
radiation dose
Epidemiological research on population effects of radiation ● Research
● Physicists
● Funding a
● Industry
● Long-term studies of patients at high risk (e.g., children,
high exposures due to occupation or accidents)
● Large prospective registries focused on defining stochastic
risks of radiation exposure
● Develop models of risk related to chronic or serial
exposure to low-dose medical radiationand mathematical models should be encouraged. Anotherarea for research is how repeated exposure should be
added to calculate risk as there are widely varying
recommended adjustment factors (dose and dose-rate
effectiveness factor). Creation of multispecialty registries
with large sample sizes or augmentation of existing
registries is a promising prospective approach that would
support development of novel methods for modeling
absorbed dose to provide more accurate patient specific
doses. However, significant obstacles exist, including
statistical validity and power, incorporation of epidemi-
ological expertise, length of follow-up, obtaining accurate
estimates of relevant organ doses, tracking nonmedical
radiation exposure, generalizability of findings, and
sources and availability of funding. At present, a number
of populations with prolonged exposure to higher than
average levels of radiation (i.e., radiation accidents or
limited radiation protection) are being studied.
Implementation: 2014–2015.
Group 2: Measuring and Reporting Radiation Dose in
Cardiovascular Imaging and Therapeutic Procedures
The accurate estimation of dose for even a single medical
exposure requires numerous assumptions and complex mod-
eling performed by medical physicists. Thus, rigorous radi-
ation dose estimates are typically obtained only in specific
situations, when detailed dosimetry is required (such as
suspected overexposure, equipment malfunction, and expo-
sure during pregnancy). Despite having significant inherent
uncertainty and unclear utility and not intended to be used
in individual patients, the radiation protection quantity of
effective dose is sometimes used for this purpose in the
absence of a better estimate. This is especially true in the
range of 50 mSv, a threshold that is rarely crossed by
single exposures for diagnostic imaging purposes. Measur-
ing and communicating effective dose provides only a
limited estimate of potential biological risk and should be
used only with great caution to estimate benefit-to-risk
of Low-Dose Radiation Associated With
Stakeholders
Implementation
Time Frame
tists
es
● Professional and scientific
organizations
● Industry
Ongoing; funding for
additional research
by 2014
tists
es
● Professional and scientific
organizations
● Hospitals and testing/
procedural labs
● Payers
Ongoing; registry by 2014isks
res
ary
sibility
scien
genci
scien
gencianalyses. However, given the heightened concern regarding
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health, effective dose is an estimate of potential detriment
that can be used to compare biological risk of different
medical procedures against each other or against back-
ground radiation, as well as to optimize safety of procedures
requiring radiation. Ongoing efforts to develop a better and
easily obtained measurement for tracking and assessing
biological risk are needed. The following 4 strategies were
recommended (see also Table 2).
Strategy 1: Establish and Implement Standards to
Ensure Consistent and Complete Recording of
Radiation Exposure and Patient Parameters Required
to Estimate Dose
The measures of exposure and patient parameters necessary
to accurately model patient radiation dose (age, sex, height,
weight, detailed anthropometry, and part of the body
exposed) are well established for most modalities, although
the biokinetics of nuclear radiopharmaceuticals are less well
known. When applicable, exposure or dose estimates should
be systematically and automatically captured at the time of
medical imaging. Properly formatted through a newly de-
veloped Digital Imaging and Communications in Medicine
(DICOM) standard, this metadata combined with mea-
sured procedural dosimetric data could be used to provide
source data for population-based studies and research to
improve our understanding of exposure, absorbed dose, and
potential biological effects. Resources to define and imple-
ment the new standards that would be required to embed
needed patient and technical factors within the practice of
medical imaging should be made a high priority at this time.
Once established, collection of these data should be auto-
mated and universal. Until this can be accomplished, all
reports should document radiation dose in terms of the
standard measurable dosimetry parameters that are used to
define diagnostic reference levels. For example, for CT the
Table 2. Strategies for Measuring and Reporting Radiation Exp
Strategy Primary Responsibilit
reate standards and mandate recording
f relevant radiation exposure and
atient parameters
● Industry
● Healthcare professionals
● Radiation physicists
xpand or develop central registries with
adiation exposure data to support best
ractices
● Payers
● Funding agencies
● Professional and scientific org
● Industry
evelop and implement standards and
ystems for communicating radiation
xposure beyond effective dose
● Healthcare professionals
● Radiation physicists
● Funding agencies
● Professional and scientific org
● Industry
educe exposures that cause
eterministic effects through enhanced
xposure monitoring and warning
rocedures
● Industry
● Hospitals and testing/procedu
● Certifying and accrediting orga
● RegulatorsCTDI(vol) is displayed on all scanner consoles manufac-
tured after 2006.
Implementation: 2012 and ongoing.
Strategy 2: Expand or Develop Central Registries
Related to Radiation Exposure and Cardiovascular
Imaging to Support Best Practices and New Research
Development of an automated, multispecialty national dose
registry (and incentives for participation) would collect
objective data for research and allow facilities to compare
doses to national reference levels, which would be a major
improvement to quality assurance practices. The Food and
Drug Administration and other organizations have pro-
moted the development of registries for the purposes of
developing national diagnostic reference levels and best
practices for facility quality assurance (12). The value of
benchmarking providers to their peers has been amply dem-
onstrated to rapidly reduce radiation dose to levels consistent
with best practices for a given exam or device (57). Registries
would help with transparency by providing authoritative and
objective data on actual exposures, which in turn would inform
more meaningful discussions by public, governmental, health
advocacy, scientific. and professional groups. Work to ensure
that patient privacy and validity of the data should be sup-
ported as part of the process.
Implementation: 2013 and ongoing.
Strategy 3: Develop and Implement Standards
for Communicating Radiation Exposure and the
Systems to Facilitate Adoption Within the
Healthcare Community
Given the complexity of developing standards in the science and
terminology of communicating radiation exposure, dose, and
potential risk from medical imaging studies to patients, providers,
and the broader community, this task will require the resources
and investment of many stakeholders. In the short term, available
measures of exposure such as dose-area product should be docu-
e and Dose in Medical Imaging
Stakeholders
Implementation
Time Frame
● Patients, public, media
● Regulators
● Professional and scientific organizations
2012
ions
● Healthcare professionals
● Professional and scientific organizations
● Certifying and accrediting organizations
● Payers
● Regulators
2013 and ongoing
ions
● Patients, public, media
● Regulators
● Payers
Ongoing
s
ons
● Patients, public, media
● Professional and scientific organizations
● Industry
● Healthcare professionals
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involving radiation use (58). To avoid conflicting language and
ariable implementation, a standard vocabulary to reduce jargon
nd the development of systems to support these standards are
eeded to provide consistent and complete information to patients
nd providers and to promote appropriate utilization. Once
reated, use of these standards should be mandatory.
Implementation: 2012 and ongoing.
trategy 4: Minimize Deterministic Effects
lthough much of the concern revolves around late, sto-
hastic effects, in very rare situations, high exposures to
iagnostic radiation can result in short-term deterministic
ffects that may occur when thresholds for biological dam-
ge are exceeded. Since these deterministic effects are
redictable, all healthcare professionals and imaging labo-
atories should be aware of them, and the dose actively
anaged throughout the procedure. In addition, robust
afety practices should be instituted to ensure real-time
etection if dose thresholds are ever approached, with
andated reevaluation of the imaging or therapeutic strat-
gy of the particular procedure.
Implementation: 2012.
Group 3: Strategies to Minimize Radiation Dose:
From Single Episodes of Care Involving
Cardiovascular Tests and Procedures,
to Systems Change
Methods exist to achieve substantial reduction in radiation
dose. However, gaps in provider knowledge, differences in
image acquisition protocols, and limited transparency lead
to delays and fragmentation in the implementation of
existing dose-reduction opportunities. Reducing the popu-
lation burden of medical ionizing radiation will require
collaboration, interventions, and accountability at the level
of individual patient care episodes, healthcare providers,
radiation physicists, imagers, and healthcare systems. The
Joint Commission has recognized the need for such systems
change and provided a strong incentive for compliance with
its Sentinel Event Alert (41).
Appropriate patient selection reinforced through decision
support tools and provider education can reduce the perfor-
mance of inappropriate medical imaging procedures (16).
The lack of incentives to “do the right thing” and engrained
practice routines that may reflect medical–legal and eco-
nomic concerns may hinder the adoption of appropriate
imaging use. Application of existing ACCF appropriate use
criteria could reduce these barriers. Tools in development
include multimodality appropriate use criteria, which will
simultaneously assess the appropriateness of testing alterna-
tives in specific clinical scenarios, including methods that do
not involve ionizing radiation and imaging performance
measures. To fully implement any of these, the healthcare
system should develop incentives for their use.
In performing appropriate studies, substantial radiation
dose reductions can be achieved by application of existingtechnologies. For example, adjustments in cardiac CT
acquisition protocols can lead to significant dose reductions
through the application of reduced tube potential, and
performance of prospectively triggered versus retrospectively
gated image acquisition in properly selected patients (59).
However, diagnostic image quality must not be compro-
mised, and the point at which dose minimization may
have an unintended negative consequence on diagnostic
accuracy remains uncertain. Prospective implementation
studies of optimal techniques and protocols suggest that
diagnostic image quality can be retained while using
dose-reduction techniques (57,60), making inconsisten-
cies in the application of dose-reduction strategies a lost
opportunity.
There are many opportunities to reduce variability in the
performance of procedures that use ionizing radiation for
guidance, such as patient shielding during fluoroscopic
procedures, reduction of fluoroscopy and cineangiography
procedural times, and image processing techniques to elim-
inate unnecessary duplicated images and radiation exposure.
Following existing and future guidelines and implementa-
tion of robust quality control measures can be accomplished
immediately. In addition, novel complementary stereotaxic
and magnetic resonance navigation technologies and non-
fluoroscopic techniques such as optical coherence tomogra-
phy ultrasound guidance (OCT/US) for anatomical assess-
ments are promising (36). Similarly in the area of
radionuclide imaging, recommendations have been made
for the use of stress-only imaging, positron emission tomog-
raphy, and adaption of new camera technology that allows a
dramatic reduction in the dose normally administered (39).
Further technical refinements will lead to new opportu-
nities for dose reduction, and an initial focus on stan-
dardizing terminology and harmonizing methods will
facilitate their implementation across technical platforms,
with avoidance of overly proprietary techniques. Preventing the
emergence of unproven modalities confused by proprietary
jargon will require demonstration of benefit/risk during the
regulatory approval process and be reimbursed such that
providers of services are strongly encouraged to adopt innova-
tive protocols.
Sustained education and quality improvement programs
can lead to meaningful radiation dose reduction (61,62).
Such programs should recognize the opportunity to engage,
not only imagers, but also ordering physicians in efforts to
achieve population dose minimization through education on
test and procedure selection. For example, dose administra-
tion should be a routine part of laboratory quality programs.
Leverage of payment models emphasizing appropriate use
and quality imaging performance could further bolster
efforts at dose minimization.
Recommended strategies toward dose minimization that
leverage existing and future technologic advances include
the following (see also Table 3).
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More Uniform Understanding and
Approach to Dose Minimization Techniques
Method 1: Adopt mandatory annual live or online training
on basic radiation safety techniques for healthcare providers
involved in the ordering or performance of medical proce-
dures using ionizing radiation. A model for this approach is
provided by current requirements for training for universal
precautions procedures mandated through hospital accred-
itation organizations and current state mandates for fluo-
roscopy training. Topics could include radiation safety,
alternatives to use of tests with ionizing radiation, and
principles of patient selection. Because there are few current
requirements for any form of radiation training for providers
who order procedures, such education should be integral to
general as well as procedural cardiology training programs
and continuing medical education.
Implementation: Before 2014.
Method 2: Adopt a professional approach through em-
phasis on the principles and practice of radiation dose
reduction as core knowledge within professional education
including cardiology and subspecialty board certification
materials and examinations.
Implementation: Before 2015.
Strategy 2: Quality Metrics—
Quantitative Reporting of Quality Metrics on Testing
Method 1: Implement internal reporting of quality metrics,
Table 3. Strategies to Minimize Radiation Dose Exposure From
Strategy Primary Respon
ducation: training ● Certifying and accrediting
● Mandatory annual online training on
basic radiation safety techniques for
healthcare professionals involved in
the ordering or performing of medical
procedures using ionizing radiation
Education: professionalism ● Professional and scientifi
● Certifying and accrediting
● Emphasize the principles and practice
of radiation dose reduction as core
knowledge within professional
certifying education for all healthcare
professionals
Quality metrics ● Professional and scientifi
● Hospitals and testing/pro
laboratories
● Develop quality metrics for internal
reporting within organizations, with
gradual transition to external reporting
Common industry/technology standards ● Industry
● Professional and scientifi
● Regulators
● Develop common protocols,
definitions, parameter settings, and
device settings that ensure basic
radiation dose minimization standards
are metincluding appropriateness of testing, use of dose minimizationstrategies, objective image quality assessments, and facility-
level radiation exposures for common testing categories.
Method 2: Once in place and validated, internal metrics
should be elevated to become national, publically reported
standards.
Implementation: Before 2013.
Strategy 3: Common Industry/Technology Standards
Method 1: Develop common protocols, definitions, param-
eter settings, and device settings that ensure satisfaction of
basic standards while allowing innovation. From a public
health standpoint, robust quality control measures which
reduce variability may provide more benefit than the latest
advances.
Method 2: Continue to reduce exposure through the
development and use of improved equipment, technology
and techniques, shielding, and validated uses of contrast
agents and radiopharmaceuticals.
Implementation: Ongoing.
Group 4: Education and Communication for
Physicians, Patients, the Public, and Media
Heightened concerns about the health effects of radiation
associated with cardiovascular tests and procedures mandate
education of healthcare professionals and the public about
the benefits and risks associated with medical exposures.
The ability to accurately assess radiation dose, to correlate
the dose with biological response, and to communicate these
complex scientific issues to the public represents a major
le Episodes of Care to Systems Change
Stakeholders
Implementation
Time Frame
nizations ● Healthcare professionals Before 2014
nizations
nizations
● Healthcare professionals Before 2015
nizations
e
● Healthcare professionals
● Payers
● Certifying and
accrediting
organizations
● Hospitals and testing/
procedure laboratories
Before 2013
nizations
● Industry
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cular imaging and the risks to stakeholders, including
patients, physicians, technologists, industry, and the general
public (see Table 4). This information exists in various
forms and is directed to varied audiences that often do not
communicate with each other, and when they do, under-
standing may not occur due to differences in presentation
and comprehension.
Strategy 1: Identify, Catalog, and
Develop Educational Resources
Published scientific and Web-based information on the
risks and benefits of ionizing radiation provided by profes-
sional and medical societies and government agencies
should be made available to the public, patients, and
professional and medical practitioners. Because accessing
this information at the appropriate level of understanding
can be difficult, it should be modified and cataloged for the
appropriate stakeholders so that it remains factual but does
not require an advanced knowledge in radiation physics to
be understood. Primary responsibility rests with professional
and medical societies and government agencies that have
sufficient knowledge to provide accurate information. Safe-
guards must be put in place to avoid having these organi-
zations lobby or market on behalf of their technologies or
members, but rather to create factual and bias-free material with
the emphasis on full explanation of risks and benefits. Such efforts
to date have included: http://www.imagewisely.org, focused on
etting practitioners to avoid unnecessary ionizing radiation
tudies and to use the lowest optimal radiation dose for
ecessary studies; http://www.pedrad.org, focused on low-
ring radiation doses in the imaging of children; and
ttp://www.radiationanswers.org, focused on explanations
f radiation and exploring myths and benefits; and the
nternational Atomic Energy Agency’s Radiation Protec-
ion of Patients (https://rpop.iaea.org/RPOP/RPoP/
ontent/About.htm). Once the existing resources have
een identified, it is expected that knowledge gaps will
equire the creation of stakeholder-targeted educational
Table 4. Strategies for Education and Communication
Strategy Primary Responsibili
Identify, catalog, and develop
education resources
● Professional and scientific organi
● Regulators
dentify and disseminate best practices ● Professional and scientific organi
● Certifying and accrediting organiz
eighten awareness of radiation ● Professional and scientific organi
● Healthcare professionals
● Research scientists
● Hospitals and testing/procedural
● Develop and test new methods of
communicating the risk and risk
benefit of low-dose medical radiation
Ongoing recognition and minimization
of unintended consequences
● All stakeholders aboveesources by appropriate professional groups. Government
gencies such as the National Institutes of Health, Food and
rug Administration, and Agency for Healthcare Research
nd Quality may have oversight and participatory roles in
his effort.
Because the majority of the needed material already exists,
he timeline is relatively short for this effort. The greatest need
or development is for simplified material aimed at ordering
hysicians, patients, the general public, and the mass media.
anagement and coordination of the effort and the distribu-
ion process represent another challenge. Although Web-based
ccess is the fastest and least expensive, accessibility maybe
imited to many of the stakeholders, and development of
lternative methods such as social media, mailings, radio, and
elevision should be considered.
Implementation: 2012.
trategy 2: Identify and Disseminate Best Practices in
iagnostic and Procedural Imaging
edical and professional societies have developed guide-
ines for when and how to perform cardiovascular imaging
tudies (16,25,37–40,42–47). This approach first looks at
he appropriateness of a given study and has been validated
y evidence that incorporation of appropriateness guidelines
nto automated decision support systems limits growth in
he numbers of medical imaging procedures (63). If a study
s inappropriate, there is usually minimal benefit, and even
minimal risk from ionizing radiation is too high. Once a
tudy is deemed appropriate, it should be performed using
he best available imaging equipment and protocols for dose
ptimization to get the most accurate diagnosis. Accredita-
ion of laboratories providing services is recommended, and
ests should be performed and images interpreted by certi-
ed physicians. Both should include requirements for dem-
nstration of radiation safety knowledge and best practices.
hese best-practice methods for imaging using ionizing
adiation need to be distributed to all the stakeholders and
nowledge requirements implemented.
Implementation: 2012–2013.
Stakeholders
Implementation
Time Frame
s ● Patients, public, media
● Healthcare professionals
2011–2012
s ● Healthcare professionals
● Industry
● Professional and scientific organizations
● Regulators
● Payers
2012–2013
s Industry ● Healthcare professionals
● Funding agencies
● Industry
Ongoing; 2015
● Patients, public, media
● Healthcare professionals
● Payers
Ongoingty
zation
zation
ations
zation
labs
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Radiation Benefits and Risks
Media reports about radiation accidents engender fear of
low-level radiation among the general public. Patients with
apprehension about radiation may hesitate to receive appro-
priate cardiovascular imaging and should be included in
conversations that recognize both benefits and risks, as befits
the need to ensure true informed consent. Healthcare providers
need to be cognizant of this fear, as well as of the potential risks
and benefits of imaging with ionizing radiation.
As part of these communications, it is important to
convey the quantitative uncertainties about the continuous
variables of dose and risk estimates. Given these uncertain-
ties, the American College of Radiology has proposed an
approach of categorizing imaging studies by relative radia-
tion levels that differ by orders of magnitude rather than
precise dose estimates. In addition to the difficulties in
expressing exposure, expressing potential risks can also be
challenging to accomplish in terms that are meaningful to
patients and clinicians. For example, the concept of “attrib-
utable lifetime risk” of cancer mortality may be difficult to
understand, even if it is compared with hazards of everyday
life such as likelihood of dying from a motor vehicle
accident or the risk of a medical error. Consideration of
stochastic radiation risks in cardiovascular care should in-
clude, in addition to incidence and mortality of cancer,
quality of life and cost to society, and should be compared
with the burden of CVD, especially if not appropriately
diagnosed or treated. Because decisions on care must be
individualized, such potential risks are best communicated
in the setting of a strong physician–patient relationship.
Implementation: 2015 and ongoing.
Strategy 4: Identify, Monitor, and
Minimize Unintended Consequences
Healthcare providers need to help patients understand the
benefits of cardiovascular imaging and minimize situations
where patients avoid potentially life-saving procedures be-
cause they involve ionizing radiation. Avoidance of cardiac
imaging procedures by the elderly or patients with short life
expectancies may ultimately limit access to the benefits of
earlier diagnosis and optimal management with improve-
ment in quality of life. Primary responsibility for avoiding
such unintended consequences for all the listed stakeholders
rests with all providers of health care who are responsible for
determining whether diagnostic or therapeutic procedures
are justified or whether there are other opportunities to
obtain equivalent information/results. Monitoring will be an
ongoing process.
Every effort must be made to keep the dose As Low As
Reasonable Achievable (ALARA) while at the same time
keeping the benefit from diagnosis and optimal manage-
ment As High As Reasonably Achievable (AHARA). We
recognize that implementing best clinical practice using
ionizing radiation and monitoring and recording radiationexposure are essential steps that must be implemented by
those providing the tests as well as by referring physicians.
This is an ongoing process.
Summary and Next Steps
The DCRI, ACCF, and AHA Think Tank was convened to
better define the issues and needs around patient radiation
safety in cardiovascular imaging and to develop an action plan
to guide future efforts. As a 1-day meeting, the discussion and
recommendations are necessarily limited in scope, and should
be seen as exploratory rather than definitive. Nevertheless,
several important lessons can be gleaned.
Continuing the progress on improving radiation safety as it
relates to cardiovascular medicine will require the efforts of
numerous stakeholders in healthcare, government, and patient
advocacy. Further enhancement of radiation safety will require the
combined efforts and continued engagement of multiple and
diverse professional groups, industry, and government. At the
same time, it is unclear who will be the “convener” or facilitator for
these efforts in cardiovascular medicine. This is a role that may fall
naturally to professional societies, such as the ACC, although to
date, imaging specialty societies such as the American Society of
Nuclear Cardiology, Society for Cardiovascular Computed To-
mography, Society for Cardiovascular Angiography and Interven-
tions, and Society of Nuclear Medicine, and radiology organiza-
tions such as the American College of Radiology and the Health
Physics Society have been more active. A first step in uniting the
efforts of multiple organizations and stakeholders is the develop-
ment of a glossary of organizations and a clearinghouse for
ongoing and planned activities. This would allow for less overlap
and a more comprehensive and collaborative approach to the
issues of radiation safety.
The lack of clarity regarding the relationship between
medical radiation and any untoward stochastic events in an
individual patient is a significant impediment to setting specific
patient safety exposure standards but does not preclude robust
quality improvement efforts. Basic and clinical research (and
the funding to support it) is needed to understand the risks of
the low-dose, multiple exposures that are characteristic of most
cardiovascular uses. Without accurate risk estimates, it is
impossible to assess the benefit-to-risk relationship for an
individual patient. However, efforts to better apply the
basic principles of radiation protection and facility-level
tracking are eminently feasible, with the collection of
population-level dose data already demonstrated to im-
prove patient care (18). Nevertheless, funding mecha-
nism(s) for the many crucial initiatives outlined in this
document remain a challenge.
At present, the infrastructure required to support dose
assessment for quality improvement purposes is not in place.
The needs range from standardization of terminology to
adjustments in equipment capabilities to automatically track
exposure, patient parameters, and dose during clinical work-
flow. Although the primary burden rests with industry, other
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perhaps by requiring compliance to achieve implementation.
Careful patient selection and avoidance of inappropriate
testing and procedures including use of ACCF appropriate
use criteria is an important Think Tank recommendation.
Another important strategy is balancing the requirement to
effectively guide each episode of care with the need to
minimize exposure. Enhancement of patient safety through
adherence to the principle of As Low As Reasonably
Achievable (ALARA) to guide protocol considerations, the
development of lower-dose radiation equipment and com-
plementary technology, and widespread application of
proven dose-reduction techniques are critical. Recent society
guidelines, technology development, and other research have
been effective to date, but the collation, dissemination, and
implementation of best practices is a particular need, and may
require “encouragement” from governmental and accredita-
tion agencies. Additional areas in which “encouragement”
may be helpful include reporting of quality metrics and
incorporation of requirements for professional certification
and maintenance of certification of personnel.
Although safety is always paramount, consideration of the
benefits as well as the risks of medical tests and procedures is in
the patient’s best interest, as is the use of sufficient radiation to
ensure diagnostic or therapeutic success. Attention must be
paid to optimizing patient care and not merely technical
information. Another unintended consequence of too-tightly
controlled radiation exposure may be the introduction of
unwarranted fear in the patient/public community leading to
refusal of necessary test and procedures. Although some of the
recommendations of this Think Tank may appear onerous to
some stakeholders, the most successful change management
initiatives balance “carrot and stick” approaches.
It is only through focused attention on an improved under-
standing of the scientific and technical considerations related to
radiation exposure and practical application of these principles
in the day-to-day care of patients that radiation safety will be
improved. For these efforts to be successful, they must be
conducted by multidisciplinary teams of medical and nonmed-
ical scientists, with support from professional societies repre-
senting the active commitment of the house of cardiology.
Funding agencies, payers, and industry must recognize the
importance of this work to public health and invest in radiation
safety. Professional societies and regulators in particular need
to ensure timely implementation of these recommendations,
and monitoring must be implemented to guard against unin-
tended consequences. It is hoped that these Think Tank
proceedings will stimulate and support meaningful continued
efforts in the future in this important area.
Abbreviations
ACCF  American College of Cardiology Foundation
AHA  American Heart Association
CT  computed tomographyCVD  cardiovascular disease
DCRI  Duke Clinical Research Institute
LNT  linear no-threshold model of radiation risk
REFERENCES
1. Chen J, Einstein AJ, Fazel R, et al. Cumulative exposure to ionizing
radiation from diagnostic and therapeutic cardiac imaging procedures:
a population-based analysis. J Am Coll Cardiol. 2010;56:702–11.
2. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose
ionizing radiation from medical imaging procedures. N Engl J Med.
2009;361:849–57.
3. Berrington de Gonzalez A, Kim KP, Smith-Bindman R, et al. Myocar-
dial perfusion scans: projected population cancer risks from current levels
of use in the United States. Circulation. 2010;122:2403–10.
4. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose
associated with common computed tomography examinations and the
associated lifetime attributable risk of cancer. Arch Intern Med.
2009;169:2078–86.
5. Brenner DJ, Hall EJ. Computed tomography—an increasing source of
radiation exposure. N Engl J Med. 2007;357:2277–84.
6. Tubiana M. Computed tomography and radiation exposure. N Engl
J Med. 2008;358:850–3.
7. Mezrich RS. Radiation exposure from medical imaging procedures.
N Engl J Med. 2009;361:2290–2.
8. Caoili EM, Cohan RH, Ellis JH, et al. Medical decision making
regarding computed tomographic radiation dose and associated risk:
the patient’s perspective. Arch Intern Med. 2009;169:1069–71.
9. Kim KP, Einstein AJ, Berrington de Gonzalez A. Coronary artery
calcification screening: estimated radiation dose and cancer risk. Arch
Intern Med. 2009;169:1188–94.
10. U.S. House of Representatives Committee on Energy and Commerce,
Subcommittee on Health Hearing on Medical Radiation: An Over-
view of the Issues, February 26, 2010. Available at: http://democrats.
energycommerce.house.gov/index.php?qhearing/medical-radiation-
an-overview-of-the-issues. Accessed August 1, 2011.
1. United States Food and Drug Administration Public Meeting: Device
Improvements to Reduce Unnecessary Radiation Exposure from
Medical Imaging, March 30–31, 2010. Available at: http://www.
fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/
ucm201448.htm. Accessed September 22, 2011.
12. United States Food and Drug Administration. White Paper: Initiative
to Reduce Unnecessary Radiation Exposure From Medical Imaging,
February 2010. Available at: http://www.fda.gov/downloads/
RadiationDoseReduction/UCM200087.pdf. Accessed September 22, 2011.
13. Schauer DA, Linton OW. NCRP Report No. 160, Ionizing Radiation
Exposure of the Population of the United States, medical exposure—
are we doing less with more, and is there a role for health physicists?
Health Phys. 2009;97:1–5.
14. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke
statistics—2011 update: a report from the American Heart Associa-
tion. Circulation. 2011;123:e18–209.
15. Gibbons RJ, Miller TD, Hodge D, et al. Application of appropriate-
ness criteria to stress single-photon emission computed tomography
sestamibi studies and stress echocardiograms in an academic medical
center. J Am Coll Cardiol. 2008;51:1283–9.
16. Hendel RC, Cerqueira M, Douglas PS, et al. A multicenter assess-
ment of the use of single-photon emission computed tomography
myocardial perfusion imaging with appropriateness criteria. J Am Coll
Cardiol. 2010;55:156–62.
17. Gibbons RJ. Finding value in imaging: what is appropriate? J Nucl
Cardiol. 2008;15:178–85.
18. International Commission on Radiological Protection. Draft Report
for Consultation: Patient and Staff Radiological Protection in Cardi-
ology: Available at: http://www.icrp.org/page.asp?id127. Accessed
September 22, 2011.
19. Thomas GS, Sugino JM, Wann S. Where have all the patients gone?
The decrease in the volume of work of cardiologists. Am Heart Hosp
J. 2010;8:44–6.
20. Shaw LJ, Narula J. Cardiovascular imaging quality-more than a pretty
picture! J Am Coll Cardiol Img. 2008;1:266–9.
1845JACC Vol. 59, No. 20, 2012 Douglas et al.
May 15, 2012:1833–47 Cardiovascular Radiation Safety Conference Report21. The 2007 Recommendations of the International Commission on
Radiological Protection. ICRP Publication 103. Ann ICRP. 2007;37:
1–332.
22. International Commission on Radiological Protection. ICRP Pub-
lication 105. Radiation protection in medicine. Ann ICRP. 2007;
37:1– 63.
22a.American Association of Physicists in Medicine. AAPM position state-
ment on radiation risks from medical imaging procedures. December 13,
2011. Available at: http://www.aapm.org/org/policies/details.
asp?id318&typePP&currenttrue. Accessed February 10, 2012.
23. Judkins MP, Abrams HL, Bristow JD, et al. Report of the Inter-
Society Commission for Heart Disease Resources. Optimal resources
for examination of the chest and cardiovascular system. A hospital
planning and resource guideline. Radiologic facilities for conventional
x-ray examination of the heart and lungs. Catheterization-angiographic
Laboratories. Radiologic resources for cardiovascular surgical operat-
ing rooms and intensive care units. Circulation. 1976;53:A1–37.
24. International Commission on Radiological Protection. Recommenda-
tions of the ICRP, ICRP Publication 26. Ann ICRP. 1977;1(3):3–6.
25. Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac
imaging: a science advisory from the American Heart Association
Committee on Cardiac Imaging of the Council on Clinical Cardiology
and Committee on Cardiovascular Imaging and Intervention of the
Council on Cardiovascular Radiology and Intervention. Circulation.
2009;119:1056–65.
26. International Commission on Radiological Protection. Radiation dose
to patients from radiopharmaceuticals (addendum 2 to ICRP publi-
cation 53). Ann ICRP. 1998;28:1–126.
27. Bolch WE, Eckerman KF, Sgouros G, et al. MIRD pamphlet No. 21: a
generalized schema for radiopharmaceutical dosimetry—standardization
of nomenclature. J Nucl Med. 2009;50:477–84.
28. Miller DL, Balter S, Noonan PT, et al. Minimizing radiation-induced
skin injury in interventional radiology procedures. Radiology. 2002;
225:329–36.
29. McCollough CH, Leng S, Yu L, et al. CT dose index and patient
dose: they are not the same thing. Radiology. 2011;259:311–6.
30. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of
atomic bomb survivors. Report 13: Solid cancer and noncancer disease
mortality: 1950–1997. Radiat Res. 2003;160:381–407.
31. NRC Committee to Assess Health Risks from Exposure to Low
Levels of Ionizing Radiation. Health Risks from Exposure to Low
Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC:
National Academies Press, 2006.
32. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to
low doses of ionizing radiation: assessing what we really know. Proc
Natl Acad Sci U S A. 2003;100:13761–6.
33. Cardis E, Vrijheid M, Blettner M, et al. The 15-Country Collabor-
ative Study of Cancer Risk among Radiation Workers in the Nuclear
Industry: estimates of radiation-related cancer risks. Radiat Res.
2007;167:396–416.
34. Langner I, Blettner M, Gundestrup M, et al. Cosmic radiation and
cancer mortality among airline pilots: results from a European cohort
study (ESCAPE). Radiat Environ Biophys. 2004;42:247–56.
35. Amis ES Jr., Butler PF, Applegate KE, et al. American College of
Radiology white paper on radiation dose in medicine. J Am Coll
Radiol. 2007;4:272–84.
36. National Council on Radiation Protection & Measurements. NCRP
Report No. 168: Radiation Dose Management for Fluoroscopically-
Guided Interventional Medical Procedures. Bethesda, MD: National
Council on Radiation Protection and Measurements, 2010.
37. Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on
radiation dose and dose-optimization strategies in cardiovascular CT.
J Cardiovasc Comput Tomogr. 2011;5:198–224.
38. Voros S, Rivera JJ, Berman DS, et al. Guideline for minimizing
radiation exposure during acquisition of coronary artery calcium scans
with the use of multidetector computed tomography: a report by the
Society for Atherosclerosis Imaging and Prevention Tomographic
Imaging and Prevention Councils in collaboration with the Society of
Cardiovascular Computed Tomography. J Cardiovasc Comput To-
mogr. 2011;5:75–83.
39. Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for
reducing radiation exposure in myocardial perfusion imaging. J Nucl
Cardiol. 2010;17:709–18.40. Chambers CE, Fetterly KA, Holzer R, et al. Radiation safety program
for the cardiac catheterization laboratory. Catheter Cardiovasc Interv.
2011;77:546–56.
41. The Joint Commission Sentinel Event Alert: Radiation risks of
diagnostic imaging. Available at: http://www.jointcommission.org/
assets/1/18/SEA_471.pdf. Accessed September 14, 2011.
42. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/
SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for
cardiac computed tomography and cardiac magnetic resonance imag-
ing: a report of the American College of Cardiology Foundation
Quality Strategic Directions Committee Appropriateness Criteria
Working Group, American College of Radiology, Society of Cardio-
vascular Computed Tomography, Society for Cardiovascular Magnetic
Resonance, American Society of Nuclear Cardiology, North American
Society for Cardiac Imaging, Society for Cardiovascular Angiography
and Interventions, and Society of Interventional Radiology. J Am Coll
Cardiol. 2006;48:1475–97.
43. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/
AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use cri-
teria for cardiac computed tomography: a report of the American
College of Cardiology Foundation Appropriate Use Criteria Task
Force, the Society of Cardiovascular Computed Tomography, the
American College of Radiology, the American Heart Association, the
American Society of Echocardiography, the American Society of
Nuclear Cardiology, the North American Society for Cardiovascular
Imaging, the Society for Cardiovascular Angiography and Interven-
tions, and the Society for Cardiovascular Magnetic Resonance. J Am
Coll Cardiol. 2010;56:1864–94.
44. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/
AATS/AHA/ASNC 2009 appropriateness criteria for coronary revas-
cularization: a report by the American College of Cardiology Founda-
tion Appropriateness Criteria Task Force, Society for Cardiovascular
Angiography and Interventions, Society of Thoracic Surgeons, Amer-
ican Association for Thoracic Surgery, American Heart Association,
and the American Society of Nuclear Cardiology. J Am Coll Cardiol.
2009;53:530–53.
45. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/
ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate
use criteria for echocardiography: a report of the American College of
Cardiology Foundation Appropriate Use Criteria Task Force, Amer-
ican Society of Echocardiography, American Heart Association,
American Society of Nuclear Cardiology, Heart Failure Society of
America, Heart Rhythm Society, Society for Cardiovascular Angiog-
raphy and Interventions, Society of Critical Care Medicine, Society of
Cardiovascular Computed Tomography, and Society for Cardiovascu-
lar Magnetic Resonance Endorsed by the American College of Chest
Physicians. J Am Coll Cardiol. 2011;57:1126–66.
46. Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for
evaluating the appropriateness of cardiovascular imaging. J Am Coll
Cardiol. 2005;46:1606–13.
47. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/
AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for
cardiac radionuclide imaging: a report of the American College of
Cardiology Foundation Appropriate Use Criteria Task Force, the
American Society of Nuclear Cardiology, the American College of
Radiology, the American Heart Association, the American Society of
Echocardiography, the Society of Cardiovascular Computed Tomog-
raphy, the Society for Cardiovascular Magnetic Resonance, and the
Society of Nuclear Medicine. J Am Coll Cardiol. 2009;53:2201–29.
48. Diagnostic reference levels in medical imaging: review and additional
advice. Ann ICRP. 2001;31:33–52.
49. Hausleiter J, Meyer T, Hermann F, et al. Estimated radiation dose
associated with cardiac CT angiography. JAMA. 2009;301:500–7.
50. Cardiovascular nuclear imaging: balancing proven clinical value and
potential radiation risk. J Nucl Med. 2011;52:1162–4.
51. Jacob P, Ron E. Late health effects of ionizing radiation: bridging the
experimental and epidemiological divide. Radiat Environ Biophys.
2010;49:109–10.
52. Preston RJ. Radiation biology: concepts for radiation protection.
Health Phys. 2004;87:3–14.
53. Prise KM. New advances in radiation biology. Occup Med (Lond).
2006;56:156–61.
66
6
6
M
C
T
G
1846 Douglas et al. JACC Vol. 59, No. 20, 2012
Cardiovascular Radiation Safety Conference Report May 15, 2012:1833–4754. Lorimore SA, Kadhim MA, Pocock DA, et al. Chromosomal instability
in the descendants of unirradiated surviving cells after alpha-particle
irradiation. Proc Natl Acad Sci U S A. 1998;95:5730–3.
55. Leith JT. Correspondence Re: H. Nagasawa and J. B. Little, Induction of
sister chromatid exchanges by extremely low doses of alpha-particles.
Cancer Res., 52: 6394–6396, 1992. Cancer Res. 1993;53:2188.
56. Wolff S. Aspects of the adaptive response to very low doses of radiation
and other agents. Mutat Res. 1996;358:135–42.
57. Bischoff B, Hein F, Meyer T, et al. Comparison of sequential and
helical scanning for radiation dose and image quality: results of the
Prospective Multicenter Study on Radiation Dose Estimates of Car-
diac CT Angiography (PROTECTION) I study. AJR Am J Roent-
genol. 2010;194:1495–9.
58. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert
consensus statement on catheter and surgical ablation of atrial fibril-
lation: recommendations for personnel, policy, procedures and follow-
up. A report of the Heart Rhythm Society (HRS) Task Force on
catheter and surgical ablation of atrial fibrillation. Heart Rhythm.
2007;4:816–61.59. Hausleiter J, Meyer T, Hadamitzky M, et al. Radiation dose estimates
from cardiac multislice computed tomography in daily practice: impact qof different scanning protocols on effective dose estimates. Circulation.
2006;113:1305–10.
0. Hausleiter J, Martinoff S, Hadamitzky M, et al. Image quality and
radiation exposure with a low tube voltage protocol for coronary CT
angiography: results of the PROTECTION II Trial. J Am Coll
Cardiol Img. 2010;3:1113–23.
1. Raff GL, Chinnaiyan KM, Share DA, et al. Radiation dose from
cardiac computed tomography before and after implementation of
radiation dose-reduction techniques. JAMA. 2009;301:2340–8.
2. International Commission on Radiological Protection. ICRP Publi-
cation 113—Education and training in radiological protection for
diagnostic and interventional procedures: chapters 1-5. Ann ICRP.
2009;(5):15–49.
3. Sistrom CL, Dang PA, Weilburg JB, et al. Effect of computerized
order entry with integrated decision support on the growth of
outpatient procedure volumes: seven-year time series analysis. Radiol-
ogy. 2009;251:147–55.Key Words: appropriate use y medical radiation y patient safety y
uality improvement.APPENDIX. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES—
DEVELOPING AN ACTION PLAN FOR PATIENT RADIATION SAFETY IN ADULT CARDIOVASCULAR MEDICINE
Participant
Name Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
J. Jeffrey
Carr
Wake Forest University
School of Medicine,
Division of
Radiologic
Sciences—Professor
& Vice Chair of
Clinical Research
None None None None ● DHHS/NIH
Grants and
Contracts*
● NIH/NHLBI†
● SCCT†
None
anuel D.
erqueira
Cleveland Clinic
Foundation—
Chairman,
Department of
Molecular &
Functional Imaging
● Astellas Pharma
US*
● Cardinal Health
● CoreLab Partners
● GE Healthcare*
● Lantheus Medical
Imaging
● Astellas
Pharma US*
● GE Healthcare*
None ● Perceptive
Informatics*
None None
Jennifer E.
Cummings
University of Toledo—
Associate Professor
of Medicine
● Boston Scientific
● Corazon
Consulting
● Medtronic
● St. Jude
None None None None ● Defendant,
case
regarding
esophageal
fistula,
2011
Pamela S.
Douglas
Duke University Medical
Center—Ursula
Geller Professor of
Research in
Cardiovascular
Diseases
● BG Medicine
● CardioDX
● Elsevier
● Heart.org†
● Medscape
Genomic
Medicine
Institute Advisory
Board/WebMD
Advisor†
● Pappas Ventures
● Patient Advocate
Foundation†
● Universal
Oncology†
● UpToDate
None ● CardioDX
● Universal
Oncology†
● Abiomed†
● AHRQ†
● Atritech†
● Department of
Defense/Defense
Advanced
Research Agency†
● The Duke
Endowment†
● Edwards
Lifesciences†
● FDA†
● Gates Foundation†
● Ikaria†
● NIH†
● Novartis†
● Pfizer†
● Viacor†
● Walter Coulter
Foundation†
● David H.
Murdock
Research
Institute†
● Translational
Research in
Oncology
(DSMB)
None
homas C.
erber
Mayo Clinic—Professor
of Medicine,
Radiology
None None None ● RESCUE Trial
(NIH/ACRIN)†
● AHA
● American
Journal of
Radiology†
● Mayo Clinic
Proceedings†
● NASCI†
● SAIP†
None
A
T
b
R
R
a
I
1847JACC Vol. 59, No. 20, 2012 Douglas et al.
May 15, 2012:1833–47 Cardiovascular Radiation Safety Conference ReportParticipant
Name Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
Debabrata
Mukherjee
Texas Tech University
Health Sciences
Center—Chief,
Cardiovascular
Medicine
None None None None ● Cleveland Clinic
Foundation
(DSMB)
None
llen J.
aylor
Washington Hospital
Center—
Co-Director,
Noninvasive Imaging
● Abbott* None None None ● Certification
Board of
Cardiovascular
Computed
Tomography†
● SAIP†
● SCCT†
None
This table represents all healthcare relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document,
at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a
business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received
y the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency.
elationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/
elationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.
*Significant relationship.
†No financial benefit.
AHA indicates American Heart Association; AHRQ, Agency for Healthcare Research and Quality; DHHS, Department of Health and Human Services; DSMB, Data Safety Monitoring Board; FDA, Food
nd Drug Administration; NASCI, North American Society of Cardiovascular Imaging; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SAIP, Society for Atherosclerosis
maging and Prevention; and SCCT, Society of Cardiovascular Computed Tomography.
